Gene transfer of hepatocyte growth factor attenuates postinfarction heart failure

Circulation

Volumn 108, Issue 10 SUPPL., 2003, Pages

  Jayasankar, Vasant ^b   Woo, Y Joseph ^a   Bish, Lawrence T ^b   Pirolli, Timothy J ^b   Chatterjee, Subhasis ^b   Berry, Mark F ^b   Burdick, Jeffrey ^b   Gardner, Timothy J ^b   Sweeney, H Lee ^b  

^a UNIVERSITY OF PENNSYLVANIA   (United States)

^b NONE

Author keywords

Angiogenesis; Apoptosis; Gene therapy; Heart failure

Indexed keywords

ADENOVIRUS VECTOR; PROTEIN BCL 2; PROTEIN BCL XL; SCATTER FACTOR; VON WILLEBRAND FACTOR;

ADJUVANT THERAPY; ANGIOGENESIS; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; APOPTOSIS; ARTICLE; CONTROLLED STUDY; CORRELATION ANALYSIS; EVALUATION; GENE TRANSFER; HEART FAILURE; HEART INFARCTION; HEART INFARCTION SIZE; HEART LEFT VENTRICLE FUNCTION; HEART LEFT VENTRICLE PRESSURE; HEART LEFT VENTRICLE SIZE; HEART LEFT VENTRICLE WALL; HEART MUSCLE CONTRACTILITY; HEART MUSCLE REVASCULARIZATION; IMMUNOHISTOCHEMISTRY; LEFT ANTERIOR DESCENDING CORONARY ARTERY; MALE; NICK END LABELING; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN FUNCTION; RAT; RAT STRAIN; THICKNESS; VIRAL GENE DELIVERY SYSTEM;

ADENOVIRIDAE; ANIMALS; APOPTOSIS; GENETIC VECTORS; HEART; HEART FAILURE, CONGESTIVE; HEART VENTRICLES; HEMODYNAMIC PROCESSES; HEPATOCYTE GROWTH FACTOR; IMMUNOHISTOCHEMISTRY; IN SITU NICK-END LABELING; MALE; MICROSPHERES; MYOCARDIAL INFARCTION; NEOVASCULARIZATION, PHYSIOLOGIC; PROTO-ONCOGENE PROTEINS C-BCL-2; RATS; RATS, INBRED LEW; VON WILLEBRAND FACTOR;

EID: 0042917782     PISSN: 00097322     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (25)

1. Mukherjee D, Bhatt DL, Roe MT, et al. Direct myocardial revascularization and angiogenesis: how many patients might be eligible? Am J Cardiol. 1999;84:598-600.
2. Ejiri M, Fujita M, Sakai O, et al. Development of collateral circulation after acute myocardial infarction: its role in preserving left ventricular function. J Cardiol. 1990;20:31-37.
3. Udelson JE, Dilsizian V, Laham RJ, et al. Therapeutic angiogenesis with recombinant fibroblast growth factor-2 improves stress and test myocardial perfusion abnormalities in patients with severe symptomatic chronic coronary artery disease. Circulation. 2000;102:1605-1610.
4. Schumacher B, Stegmann T, Pecher P. The stimulation of neoangiogenesis in the ischemic human heart by the growth factor FGF: first clinical results. J Cardiovasc Surg. 1998;39:783-799.
5. Ruel M, Laham RJ, Parker JA, et al. Long-term effects of surgical angiogenic therapy with fibroblast growth factor 2 protein. J Thorac Cardiovasc Surg. 2002;124:28-34.
6. Bussolino F, Di Renzo MF, Ziche M, et al. Hepatocyte growth factor is a potent angiogenic factor which stimulates endothelial cell motility and growth. J Cell Biol. 1992;119:629-641.
7. Matsumoto K, Nakamura T. Emerging multipotent aspects of hepatocyte growth factor. J Biochem. 1996;119:591-600.
8. Fliss H and Gattinger D. Apoptosis in ischemic and reperfused rat myocardium. Circ Res. 1996;79:949-956.
9. Liu Y-H, Yang X-P, Nass O, et al. Chronic heart failure induced by coronary artery ligation in Lewis inbred rat. Am J Physiol. 1997;272: H722-H727.
10. Ono K, Matsumori A, Shioi T, Furukawa Y, Sasayama S. Enhanced expression of hepatocyte growth factor/c-Met by myocardial ischemia and reperfusion in a rat model. Circulation. 1997;95:2552-2558.
11. Sato T, Fujieda H, Murao S, et al. Sequential changes of hepatocyte growth factor in the serum and enhances c-Met expression in the myocardium in acute myocardial infarction. Jpn Circ J. 1999;63:906-908.
12. Boccaccio C, Gaudino G, Gambarotta G et al. Hepatocyte growth factor (HGF) receptor expression is inducible and is part of the delayed-early response to HGF. J Biol Chem. 1994;269:12846-12851.
13. Nakamura T, Mizuno S, Matsumoto K, et al. Myocardial protection from ischemia/reperfusion injury by endogenous and exogenous HGF. J Clin Invest. 2000;106:1511-1519.
14. Van Belle E, Witzenbichler B, Chen D, et al. Potentiated angiogenic effect of scatter factor/hepatocyte growth factor via induction of vascular endothelial growth factor. Circulation. 1998;92:381-390.
15. Soeki T, Tamura Y, Sinohara H, et al. Role of circulating vascular endothelial growth factor and hepatocyte growth factor in patients with coronary artery disease. Heart Vessels. 2000;15:105-111.
16. Watanabe K, Fukuda H, Sueda S, et al. Metabolism of hepatocyte growth factor in the heart in patients with coronary artery disease: implication for coronary arteriosclerosis. Card Drugs and Ther. 2001;15:147-153.
17. Yasuda S, Goto Y, Baba T, et al. Enhanced secretion of cardiac hepatocyte growth factor from an infarct region is associated with less severe ventricular enlargement and improved cardiac function. J Am Coll Cardiol. 2000;36:115-121.
18. Nidorf SM, Siu SC, Galambos G, et al. Benefit of late coronary reperfusion on ventricular morphology and function after myocardial infarction. J Am Coll Cardiol. 1992;20:307-313.
19. Horie H, Takahasi M, Minai K, et al. Long-term beneficial effect of late reperfusion for acute anterior myocardial infarction with percutaneous transluminal coronary angioplasty. Circulation. 1998;98:2377-2382.
20. White HD, Norris RM, Brown MA, et al. Left ventricular end-systolic volume as the major determinant of survival after recovery from myocardial infarction. Circulation. 1987;76:44-51.
21. Cheng W, Kajstura J, Nitahara JA, et al. Programmed cell death contributes to ventricular remodeling after myocardial infarction in rats. Exp Cell Res. 1996;226:316-327.
22. Morishita R, Higake J, Hayashi SI, et al. Role of hepatocyte growth factor in endothelial regulation: prevention of high D-glucose-induced endothelial cell death by prostaglandins and phosphodiesterase type 3 inhibitor. Diabetologia. 1997;40:1053-1061.
23. Chatterjee S, Stewart AS, Bish LT, et al. Viral gene transfer of the anti-apoptotic factor Bcl-2 protects against chronic post-ischemic heart failure. Circulation. 2002;106(suppl I):I212-I217.
24. Shanoff HM, Little JA, Csima A, et al. Heart size and ten-year survival after uncomplicated myocardial infarction. Am Heart J. 1969;78:608-614.
25. St John Sutton M, Pfeffer MA, Plappert T, et al. Quantitative two-dimensional echocardiographic measurements are major predictors of adverse cardiovascular events after acute myocardial infarction: the protective effects of captopril. Circulation. 1994;89:68-75.